What Are the Treatment Options for Lobular Carcinoma In Situ (LCIS)?

Lobular Carcinoma in Situ (LCIS) is somewhat of a misnomer in that it is not a cancer, but a “pre-malignant” condition in which there are abnormal cells present in the glands (lobules) of the breast. Patients who have been diagnosed with LCIS do not have cancer, but are at a higher risk of developing breast cancer than the general population. For this reason they require closer observation and shorter intervals between screening mammograms. In patients with a strong family history of breast cancer, or those at very high risk, hormonal therapy with Tamoxifen may be used to reduce the risk of invasive breast cancer. Surgery is generally not performed for LCIS alone.

Interestingly, patients with LCIS who develop invasive cancer usually develop invasive ductal cancer of the breast. Also, 40% of patients with LCIS who develop invasive cancer may develop cancer in both breasts. For this reason a prophylactic mastectomy of the normal breast is often performed at the time of mastectomy for the diseased breast in patients with LCIS who have developed invasive cancer.

How to Know if You are at Risk for Breast Cancer

Featured

Anything that affects your chances of getting a disease is called a risk factor. Certain risk factors are linked to certain conditions, such as cancer. Different cancers have different risk factors. For example, of the approximately 200,000 women in the United States that are diagnosed with breast cancer each year, not all will have the same risk of developing breast cancer during their lifetimes. Some women will have certain risk factors which will increase the likelihood that they will develop breast cancer over others.

However, just because you have a risk factor—or multiple risk factors—does not mean that you are going to end up with breast cancer. In fact, many women who have one or more risk factors never get breast cancer. On the other hand, many cases of breast cancer occur in women with no apparent risk factors. The biggest advantage in recognizing women at risk for developing breast cancer lies in the ability to identify those individuals who may benefit most from screening and preventative measures. After all, there are some risk factors that can be modified. The following are some of the risk factors that are associated with the development of breast cancer:

Age

Your risk of developing breast cancer increases as you get older. About two-thirds of breast cancers are found in women older than 55 years of age.
Family history of breast cancer.

Breast cancer risk is higher among women whose immediate blood relatives have the disease.

If you have one first-degree relative (mother, sister, or daughter) with breast cancer, then your risk of getting breast cancer is approximately doubled. Having two first-degree relatives increases your risk about 3-times more than normal.

About 5% to 10% of the time, breast cancer is the result of genetic defects which are inherited from a parent. The most common of these are the BRCA1 and BRCA2 gene mutations. Women with this form of hereditary mutation tend to develop breast cancer at a younger age than average. These cancers also more often involve both breasts and are associated with the development of cancer in other organs, such as the ovaries.

Not all breast cancer is family related though. Of all women who get breast cancer, 85% do not have a family history of the disease.
Previous History of Breast Cancer in the Opposite Breast

A woman who has already had cancer in one breast is 3- to 4- times more likely to develop a new cancer in the other breast. This is one of the strongest risk factors for breast cancer development.
Dense breast tissue

Women with dense breast tissue have more glandular tissue and less fatty tissue, and have a higher risk of breast cancer. Unfortunately, the dense breast tissue also makes it harder for doctors to see abnormalities on mammograms.
Menstrual periods

Women who started menstruating at an early age (the average age is 12) and/or experienced menopause at a later age (average age 55) have a slightly higher risk of breast cancer. This may again be related to the increased levels of estrogen in these patients.
Childbearing

Women who have had no children (Nulliparous) have a mildly higher risk of breast cancer than the general population. In contrast, women who have had many pregnancies show a reduced breast cancer risk. This is probably because pregnancy reduces the total number of menstrual cycles throughout life, which means less unbalanced estrogen exposure.
Oral Contraceptive Use

Studies have found that women using oral contraceptives (birth control pills) have a slightly greater risk of breast cancer than women who have never used them. Once the pills are stopped, the risk decreases, reaching normal levels after about 10 years.
Being Overweight or Obese

Your body’s fat tissue produces estrogen. When women enter menopause, the ovaries slowly stop making estrogen. Most of the estrogen production then shifts from the ovaries to the fat tissue. The more fat you have, the more estrogen you will produce. This will increase your chances of developing breast cancer.

If you notice, there is one main theme that is linked to all the major breast cancer risk factors: Estrogen. Just being a woman itself is a risk factor for developing breast cancer. Both men and women have breast tissue; women just have more because they are exposed to more estrogen and progesterone. In fact, men can also develop breast cancer, and male breast cancer accounts for 1% of all breast cancers diagnosed annually.

So, do you have any breast cancer risk factors? Do you know anyone with breast cancer risk factors? Remember, risk factors or not, all women should speak with their doctors’ about breast cancer screening, and ways to lower your breast cancer risk factors if present.

FDA recommends removal of Avastin for treatment of Breast Cancer

The FDA notified healthcare professionals and patients that it is recommending removing the breast cancer indication for Avastin (bevacizumab) because the drug has not been shown to be safe and effective for that use. The drug itself is not being removed from the market and this action will not have any immediate impact on its use in treating breast cancer. Today’s action will not affect the approvals for colon, kidney, brain, and lung cancers. The FDA is making this recommendation after reviewing the results of four clinical studies of Avastin in women with breast cancer and determining that the data indicate that the drug does not prolong overall survival in breast cancer patients or provide a sufficient benefit in slowing disease progression to outweigh the significant risk to patients. None of the studies demonstrated that patients receiving Avastin lived longer, and patients receiving Avastin experienced a significant increase in serious side effects. These risks include severe high blood pressure; bleeding and hemorrhage; the development of perforations (or “holes”) in the body, including in the nose, stomach, and intestines; and heart attack or heart failure.

Patients currently receiving Avastin for breast cancer should speak with their oncologists about whether to continue their treatment or explore other treatment options.

Choosing Between Lumpectomy and Mastectomy

Many women with early-stage breast cancers have the option of choosing between a breast-conserving surgery such as a lumpectomy or a mastectomy which removes the entire breast tissue.

The main advantage of a lumpectomy is that it allows a woman to keep most of her breast. A disadvantage is the usual need for radiation therapy — most often for 5 to 6 weeks — after surgery. A (very) small number of women having breast-conserving surgery may not need radiation, while a small percentage of women who undergo mastectomy will still need radiation therapy to the breast area.

When deciding between a lumpectomy and mastectomy, be sure to get all the facts. Often times women have an initial preference for mastectomy. This is a natural “gut reaction” to the diagnosis of cancer, as we would want to take everything out as quickly as possible. The fact of the matter, however, is that in most cases mastectomy does not give you any better chance of long-term survival or a better outcome from treatment than lumpectomy. Studies following thousands of women for more than 20 years show that when a lumpectomy can be done, doing a mastectomy instead does not provide any better chance of survival.

Most women and their doctors prefer lumpectomy and radiation therapy when it’s a reasonable option, but your choice will depend on a number of factors, such as:

  • How you feel about losing your breast
  • How you feel about getting radiation therapy (and the side effects that go along with it)
  • How far you would have to travel and how much time it would take to have radiation therapy
  • Whether you think you will want to have more surgery to reconstruct your breast after having a mastectomy
  • Your preference for mastectomy as a way to get rid of all your cancer as quickly as possible
  • Your fear of the cancer coming back

For some women, mastectomy may clearly be a better option. For example, lumpectomy or breast conservation therapy is usually not recommended for:

  • Women who have already had radiation therapy to the affected breast
  • Women with 2 or more areas of cancer in the same breast that are too far apart to be removed through 1 surgical incision, while keeping the appearance of the breast satisfactory
  • Women whose initial lumpectomy along with re-excision(s) has not completely removed the cancer
  • Women with certain serious connective tissue diseases such as scleroderma or lupus, which may make them especially sensitive to the side effects of radiation therapy
  • Pregnant women who would require radiation while still pregnant (risking harm to the fetus)
  • Women with large tumors (greater than 5 cm) that didn’t shrink very much with neoadjuvant chemotherapy
  • Women with inflammatory breast cancer
  • Women with a cancer that is large relative to her breast size

Other factors may need to be taken into account as well. For example, young women with breast cancer and a known genetic (BRCA) mutation are at very high risk for a second cancer. These women often consider having the other breast removed to reduce this risk, and so may choose to have the cancer treated with a mastectomy, as well. A double mastectomy may be done to both treat the cancer and reduce the risk of a second breast cancer.

What is an Adequate Margin for Breast-Conserving Surgery? Surgeon Attitudes and Correlates

Michelle Azu, MD, Paul Abrahamse, MA, Steven J. Katz, MD, MPH, Reshma Jagsi, MD, DPhil, and Monica Morrow, MD

Breast Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York; Department of Internal Medicine, University of Michigan, Ann Arbor, MI; Department of Radiation Oncology, University of Michigan, Ann Arbor, MI

ABSTRACT

Background. Re-excision is common in breast-conserving surgery (BCS), partly due to lack of consensus on margin definitions. A population-based surgeon sample was used to determine current attitudes toward margin width and identify characteristics associated with margin choice. Methods. Breast cancer patients treated from 2005 to 2007 were identified from Los Angeles and Detroit Surveillance, Epidemiology, and End Results (SEER) registries. Pathology reports were used to identify their surgeons, who were surveyed (n = 418). Response rate was 74.6% (n = 312). Mean surgeon age was 51.9 years, 17.8% were female, and mean number of years in practice was 18.5. Results. Wide variation in margin selection was noted among surgeons, and did not differ for invasive cancer and ductal carcinoma in situ (DCIS). In a scenario of T1 invasive cancer, 11% of surgeons endorsed margins of tumor not touching ink (TNTI), 42% of 1–2 mm, 28% of C5 mm, and 19% [1 cm as precluding need for re-excision before radiotherapy. On multivariate analysis, having 50% or more of practice devoted to breast cancer independently predicted smaller margin choice (p = 0.03). For a patient with a 1.4-cm grade 2 estrogen receptor (ER)-positive DCIS without radiotherapy (RT) planned, 3% of surgeons chose TNTI, 12% 1–2 mm, 25% C5 mm, and 61% [1 cm as sufficient without re-excision. In the scenario of DCIS without RT, breast specialization independently predicted larger margin choice (p = 0.03). Gender and years in practice were not predictive of margin choice. Conclusions. Wide variation in BCS margin definition exists. Variation is similar for invasive cancer and DCIS with RT, with more specialized surgeons choosing smaller margins. In DCIS without RT, more specialized surgeons favored larger margins. A standardized margin definition may significantly affect re-excision rates.

There is no widely adopted definition of an adequate margin in patients with invasive or in situ breast carcinoma undergoing breast-conserving surgery (BCS) with subsequent radiation therapy. In the prospective randomized trials of breast-conservation therapy (BCT) that showed survival to be equivalent to that seen with mastectomy, only the National Surgical Adjuvant Breast and Bowel Project (NSABP) B06 study used a microscopic definition of a negative margin, which was tumor not touching ink.While it is clear that positive margin status, defined as tumor touching ink, is an important predictor of ipsilateral breast tumor recurrence (IBTR), consistent evidence that more widely clear margins decrease the risk of IBTR is lacking.Re-excision is a common procedure in women undergoing BCS, and reported rates of re-excision vary widely.In a population-based survey of 704 women with DCIS and stage 1 and 2 cancer undergoing successful BCS in 2005–2006, 26% reported that they had a re-excision.We hypothesized that the lack of a standard definition of an adequate negative margin among surgeons contributes to high rates of re-excision, sought to determine the current definition of a negative margin among surgeons, and sought to define what surgeon characteristics are associated with margin preference for patients with ductal carcinoma in situ (DCIS) and invasive breast cancer.

METHODS

We performed a survey of a population-based sample of 2,680 women in the metropolitan areas of Los Angeles, CA, and Detroit, MI, aged 20–79 years and diagnosed with primary DCIS and invasive carcinoma (American Joint Committee on Cancer stage 1–3) between August 2005 and February 2007 using Surveillance, Epidemiology, and End Results (SEER) program registries.The details of the patient study are reported elsewhere.  Pathology reports were used to identify one surgeon or more for 98.9% of the patient sample. Surgeons were contacted by mail and asked to participate in a brief, self-administered survey which used clinical scenarios to evaluate preferences regarding margins for BCS. Surgeons were mailed a packet containing a letter of introduction, the survey, and a US $40 subject fee approximately 14 months after the start of the patient survey. We used a modified version of the Dillman method to optimize responses.A second survey was mailed to nonrespondents 4 weeks after the first survey; a phone call was made to nonrespondents 4 weeks after the second survey; a third survey was mailed on a case-by-case basis. We identified 418 surgeons of whom 318 returned completed questionnaires (response rate, 76.1%). Surgeon survey measures were developed based on an extensive review of the literature, our prior research, and a conceptual model. The content included questions pertaining to demographics (age, gender, years in practice), practice volume (percentage of total practice time devoted to breast cancer treatment, number of definitive breast carcinoma surgery procedures per year), and hospital practice setting. Breast surgery practice volume was created by recording the percentage of total practice time devoted to breast-carcinoma-related surgery into three categories: \15%, 16–49%, and [50%. We chose this measure rather than surgeon recall of the number of procedures performed per year because there were fewer missing observations. However, the same results were obtained when data was analyzed with the number of procedures as the independent variable.

To assess surgeon attitudes about appropriate margin width, we used the following case scenarios. Scenario A: A 60-year-old woman presents with a 0.8-cm mass in the upper outer quadrant of a large breast. A core biopsy shows grade 3 infiltrating ductal carcinoma, ER/progesterone receptor (PR) negative, human epidermal growth factor receptor-2 (HER-2) negative. The patient received lumpectomy and sentinel node biopsy with radiotherapy planned. Scenario B: A 60-year-old woman presents with a cluster of calcifications in the upper outer quadrant of the right breast on screening mammogram. A core biopsy shows DCIS. Needle localization and excision demonstrate a 1.4-cm grade 2 DCIS, ER positive. The patient opts for radiation therapy. Scenario C: A 60-year-old woman presents with a cluster of calcifications in the upper outer quadrant of the right breast on screening mammogram. A core biopsy shows DCIS. Needle localization and excision demonstrate a 1.4-cm grade 2 DCIS, ER positive. The patient opts not to receive radiotherapy. For each scenario, surgeons were asked ”Which negative margin width precludes the need for re-excision?” Choices offered were tumor cells not touching ink, greater than 1–2 mm, greater than 5 mm, and greater than 1 cm.

Analysis

We first described characteristics of the respondent surgeon population. We then described the distribution of responses to the three scenarios and examined the effect of surgeon age, gender, practice setting, and proportion of practice devoted to breast cancer on response using the chi-squared test. Logistic regression was then used to examine the interaction between surgeon volume and selected demographic variables.

RESULTS

The mean age of the 318 respondent surgeons was 51.9 years (range 40–63 years), the mean number of years in practice was 18.5, and 17.8% of surgeons were female. Breast cancer surgery accounted for 15% or less of the practice of 46% of respondents, and 16–49% of the practice of 37% of respondents, while 17% of the surgeons studied devoted greater than 50% of their practice to breast surgery.

No significant differences in preferred margins for the invasive cancer with radiotherapy (RT) scenario (A) versus the DCIS with RT scenario (B) were seen, and 82% of those surveyed chose the same response to both questions. A margin of tumor not touching ink was the least frequently endorsed margin for either of these scenarios, and was selected by only 11 and 10% of respondents, respectively. For each of these scenarios, approximately half of the surgeons favored margins of 5 mm or less, and half favored larger margins. For scenario C (DCIS with no RT) only 14% of surgeons favored margins less than 5 mm, and 61% endorsed margins greater than 1 cm.

Consistent patterns across both the invasive cancer scenario (A) and the DCIS with RT scenario (B) were not observed for most demographic characteristics. For example, a significant difference in margin preference on the basis of gender was seen for invasive cancer, where 67% (n = 37) of female surgeons endorsed a margin of 2 mm or less compared with only 50% of male surgeons (n = 124; p = 0.007), In contrast, no gender-based differences in margin preference were seen for the DCIS with RT scenario, with 52% of male surgeons and 54% of female surgeons selecting a margin of 2 mm or less. Gender was also not predictive of margin selection in the DCIS with no RT scenario. Age was also not a significant determinant of margin preference. In the invasive scenario, the mean surgeon ages for those who selected margin widths of tumor not touching ink, [1–2 mm, and [5mm were 53.7 ± 10 years, 50.7 ± 10 years, and 52.4 ± 10 years, respectively. A similar lack of significant differences on the basis of age was seen in the other scenarios.

The proportion of the practice devoted to breast cancer surgery was a significant predictor of margin preference in univariate analysis. Surgeons devoting 50% or more of their practice to breast cancer patients favored smaller margins (p = 0.002) for the invasive cancer scenario. A similar trend was seen for the DCIS with RT scenario, but did not reach statistical significance. In contrast, surgeons treating more breast cancer were likely to favor larger margins for DCIS treated without RT. Most other structural attributes of practice were not associated with margin preference in any consistent fashion. Discussion of the treatment plan with a radiation oncologist, medical oncologist or plastic surgeon prior to surgical therapy or participation in a multidisciplinary tumor board was not associated with margin preference. Practice setting [National Cancer Institute (NCI)-designated cancer center, university affiliation, or practice in a hospital with an American College of Surgeons-approved cancer program] was also not associated with margin preference. However, surgeons favoring smaller margins for the invasive cancer scenario and the DCIS with RT scenario were more likely to have residents associated with their practice (invasive cancer 59 vs. 49%, p = 0.01; DCIS plus RT 59 vs. 47%; p = 0.007) than those favoring larger margins. Finally, surgeon propensity for BCS in the invasive scenario, measured using a six-point Likert scale of strongly, moderately, weakly favor lumpectomy plus RT, or strongly, moderately, weakly favor mastectomy, did not correlate with choice of margin width, although almost all respondents strongly or moderately favored lumpectomy.

Surgeons devoting more than 50% of their practice to breast cancer surgery were much less likely to favor large margins than their counterparts with 15% or less of the practice devoted to breast surgery for the invasive cancer scenario. In contrast, for DCIS treated without RT, surgeons treating a high proportion of breast cancer cases were much more likely to favor a larger margin than surgeons for whom breast cancer comprised 15% or less of their practice. The proportion of practice devoted to breast cancer was not predictive of margin status for DCIS treated with RT, and neither gender nor years in practice were predictive of margin width for any scenarios.

DISCUSSION

Our study demonstrates wide variation among surgeons in the Los Angeles County and Metropolitan Detroit areas regarding the definition of an adequate negative margin. None of the margin definitions provided (tumor not on ink, [1–2 mm, [5 mm, [1 cm) were endorsed by more than half the respondents when treatment with BCS included radiotherapy, regardless of whether the diagnosis was invasive cancer or DCIS. More specialized surgeons (i.e., those with [50% of their practice devoted to breast disease) were significantly more likely to endorse smaller margins in the invasive cancer scenario than their nonspecialized counterparts, but years in practice and gender did not influence margin preference. Somewhat surprisingly, other measures of surgeon practice were not correlated with attitudes about margin status, including affiliation with a specialized cancer treatment setting or the extent of multidisciplinary treatment decision-making (presence of a tumor board, extent to which the surgeon discussed treatment plans with other specialists prior to surgery).

Similar variation in the definition of a negative margin has been observed among North American and European radiation oncologists. Taghian et al. surveyed 702 North American radiation oncologists and 431 European radiation oncologists.Tumor not touching ink was accepted as a negative margin by 46% of North Americans and only 28% of Europeans. No regional variations in the definition of a negative margin were observed within different parts of the USA, suggesting that our findings from Los Angeles and Detroit are generalizable to surgeons throughout the country. Similar to the findings of our study, Taghian et al. did not observe variation in the definition of a negative margin based on practice in an academic or a nonacademic setting.We extend this finding as we did not find significant correlations between surgeon attitudes about margin width and factors such as gender, surgeon specialization, institutional specialization, or degree to which the practice has multidisciplinary decision support models.

The lack of consensus in margin definition reflects the lack of a standardized definition of a negative margin in the original randomized trials of BCT. While the NSABP-06 study used the definition of tumor cells not touching ink, other randomized trials appeared to employ more widely clear margins.Entrance criteria for the Institute Gustave Roussy study included a gross margin of 2 cm, while the Milan I trial specified removal of a ”quadrant” of the breast.The use of these gross definitions means that the actual microscopic margin widths in these studies ranged from margins involved with tumor to margins negative by several centimeters depending upon the microscopic extent of disease and the location of the tumor within the quadrant. This unmeasured variation precludes the use of data from the randomized trials to analyze the impact of negative margin width on ipsilateral breast tumor recurrence (IBTR) after controlling for other variables. It is not particularly surprising that retrospective studies have not resulted in consistent findings regarding margin width and IBTR.Margin assessment is a sampling of the surface of the lumpectomy specimen, and both the technique of sampling and the number of specimens examined are variable. Wright et al. reported that the positive margin rate at Memorial Sloan-Kettering Cancer Center increased from 15 to 49% when the technique of pathologic assessment of margins changed from perpendicular margins to shaved margins, although surgical practice did not change in that interval.Graham et al. noted that the mean height of the lumpectomy specimen (anterior to posterior distance) as measured by the surgeon in the operating room was decreased by 54% when measured in the pathology laboratory when compression devices were used for specimen X-rays, and by 41% when these devices were not used, introducing a major source of variation in the measurement of anterior and posterior margin width.In addition, Wiley et al. observed that the likelihood of identifying residual invasive cancer after an initial lumpectomy decreases in a statistically signi?cant way as the time from the initial surgical procedure increases, introducing another source of variation in margin assessment.Given all these potential sources of variation, it is not surprising that differences of millimeters in margin width have not been shown to correlate with rates of IBTR. In addition, it has become clear that factors other than tumor burden, as measured by margin width, have a major impact on the risk of IBTR. The use of adjuvant systemic therapy significantly reduces IBTR, and newer information suggests that the intrinsic biologic subtype of the breast cancer may also be related to the risk of IBTR.This is a rapidly evolving field, and it is possible that surgeons who devote a greater proportion of their practice to breast cancer management may be more aware of the impact of factors other than margin width on IBTR than their counterparts who treat breast cancer less frequently, and therefore place less emphasis on obtaining more widely clear margins.

In DCIS the situation is slightly different since the identification of subtypes of DCIS with a different propensity to develop invasive cancer has proven elusive. In the randomized studies that examined the use of RT in DCIS, the only microscopic margin definition employed was tumor not touching the ink.So it is reassuring that our study indicates that surgeons who favor this definition for invasive cancer have a similar approach in DCIS treated with RT. The selection of patients with DCIS for treatment without RT remains a matter of controversy. However, a well-publicized single-institution study has suggested that excision to a margin of 1 cm or greater obviates the need for RT in DCIS.Although the results of this study have not been reproduced prospectively, it is likely that these data account for the overall preference for more widely clear margins in the scenario of DCIS treated with excision alone.The difference between high-and low-volume surgeons observed in this scenario, which is in the opposite direction of that observed for patients treated with RT, is not readily explainable but may reflect a greater tailoring of margin status to the individual patient scenario by more specialized surgeons.

Our study has important implications for clinical care. Re-excision rates in the literature are highly variable and range from 20 to 60%.In a population-based study of 800 women attempting BCS in 2006, the procedure was successful in 88%, but 26% required re-excision.Re-excision necessitates a second trip to the operating room with its attendant costs, delays the initiation of adjuvant systemic therapy, and leads to patient anxiety. Our results suggest that a significant proportion of re-excisions are done in patients with negative margins (tumor not touching ink) because of the use of alternate margin definitions not supported by consistent high-quality clinical data. The variability in margin definition is increasingly being recognized as a problem and led participants at both the 2008 Bidenkopf International Consensus Conference on the Local Therapy of Breast Cancer and the 2009 St. Gallen Consensus Conference on Early Stage Breast Cancer to endorse tumor not touching ink as the standard definition of an adequate negative margin in women with invasive carcinoma, and to suggest that margins be considered in the context of multiple factors known to influence the risk of IBTR.Our results suggest that better standards need to be broadly adopted by the surgical community at large, because variation in surgeon attitudes was observed across surgeon and practice subgroups.

Our study does have limitations. The margin widths reported are based on surgeon responses to case scenarios and may not reflect actual clinical practice, particularly the use of re-excision when the ideal margin is not achieved. Additionally, the survey population is geographically limited to two large metropolitan areas which may not be reflective of United States practice patterns as a whole, although a study examining this issue in the radiation oncology community did not demonstrate differences in margin preference based on geographic location within the United States.In spite of these concerns, our study documents clear variation among surgeons in the definition of what negative margin width precludes the need for re-excision. Achieving a more widespread consensus on this issue has the potential to reduce costs, to decrease the use of unnecessary mastectomies, and perhaps to increase patient acceptance of BCS at a time when mastectomy rates are rising.

CONCLUSION

Definition of an adequate margin varies, and clinical trials data supporting tumor not touching ink are not widely accepted. Definition of acceptable margin width is similar for invasive cancer and DCIS with RT, with more specialized surgeons favoring smaller margins. In DCIS treated without RT, more specialized surgeons are significantly more likely to favor larger margins. Factors not significantly associated in either invasive cancer or DCIS include age, gender, years in practice, and multidisciplinary specialist perioperative consultations. Adoption of a standard margin definition has the potential to significantly affect re-excision rates.